![Mark Bodmer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Bodmer
Directeur Général chez
Nucleome Therapeutics Ltd.
Profil
Mark W.
Bodmer is currently Chief Executive Officer at Nucleome Therapeutics Ltd. Former positions include Chief Executive Officer at Biotica Technology Ltd., Hexagen Plc, and Lorantis Ltd. (1999–2004); Director at The Bioindustry Association (2015–2016); Principal at The Wellcome Trust Ltd., Schroder Ventures Holdings Plc, Apax, and JPMorgan Partners Europe; Vice President-New Medicines Therapeutics at UCB SA (2012–2016); Senior Vice President-Research & Development at Incyte Pharmaceuticals, Inc. (1998–1999); and Chief Scientific Officer, President-R&D at Evelo Biosciences, Inc. (2016–2024).
Education includes undergraduate and doctorate degrees from the University of Cambridge.
Postes actifs de Mark Bodmer
| Sociétés | Poste | Début |
|---|---|---|
Nucleome Therapeutics Ltd.
 Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecular drugs for autoimmune diseases | Directeur Général | - |
Anciens postes connus de Mark Bodmer
| Sociétés | Poste | Fin |
|---|---|---|
| EVELO BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 01/02/2024 |
The Bioindustry Association
 The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services Operates as a association to encourage and promote bioscience sector | Directeur/Membre du Conseil | 01/04/2016 |
| UCB | Corporate Officer/Principal | 01/04/2016 |
Lorantis Ltd.
 Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | President | 01/01/2004 |
Incyte Pharmaceuticals, Inc.
 Incyte Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Directeur Technique/Scientifique/R&D | 01/01/1999 |
Formation de Mark Bodmer
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
31
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
The Wellcome Trust Ltd.
 The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous Provides welfare and charitable services | Miscellaneous |
Biotica Technology Ltd.
 Biotica Technology Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
UCB SA
 UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Schroder Ventures Holdings Plc
 Schroder Ventures Holdings Plc Financial ConglomeratesFinance Private equity firm | Finance |
Incyte Pharmaceuticals, Inc.
Incyte Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Hexagen Plc
 Hexagen Plc BiotechnologyHealth Technology Develops technology for discovery of single nucleotide polymorphisms | Health Technology |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lorantis Ltd.
Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Health Technology |
Apax
 Apax Home FurnishingsConsumer Durables Manufactures furniture | Consumer Durables |
JPMorgan Partners Europe
 JPMorgan Partners Europe Financial ConglomeratesFinance Private equity group | Finance |
The Bioindustry Association
The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services Operates as a association to encourage and promote bioscience sector | Commercial Services |
Evelo Biosciences, Inc.
 Evelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapeutics for small intestine related diseases | Health Technology |
Nucleome Therapeutics Ltd.
Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecular drugs for autoimmune diseases | Health Technology |
